Novo Nordisk: interim results above expectations
(CercleFinance.com) - On Friday Novo Nordisk announced H1 results that are slightly above the consensus, which led to its share rising on the Copenhagen Stock Exchange.
In the first half of the year, the Danish group - the world leader in the treatment of diabetes - posted operating profit that is up 12% at 27.6 billion Danish kronor (about 3.6 billion euros).
Meanwhile, sales rose by 9% to 59.3 billion kronor, with 5% growth at constant exchange rates.
The biopharmaceutical company has also raised its full-year guidance, thanks to the successful launch of Ozempic, its new type-2 diabetes treatment, taken by a weekly injection.
Novo says it is now expecting 4% to 6% growth in its operating profit in 2019 in local currency, compared to 2% to 6% previously.
Sales at constant exchange rates are expected to increase by 4% to 6% this year, up from a previous forecast range of 2% to 5%.
Just before midday, the share was up 0.9%, in a Danish market that is pretty much flat.
Copyright (c) 2019 CercleFinance.com. All rights reserved.